At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 39 enrolled
Drug / intervention
FOLFOX6 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)
In Brief
A Phase 2 clinical trial evaluating FOLFOX6, RT with concurrent chemotherapy, and 1 other intervention for Colon Cancer and Rectal Cancer. Completed, enrolled 39 participants across 3 sites.
Detailed Summary
The purpose of this study is to find out how well patients with cancer of the rectum do if they get all of their other treatment - chemotherapy by itself followed by chemotherapy and radiation together - before surgery. Patients have recently been diagnosed with rectal cancer, and the doctors have recommended neo-adjuvant chemo treatment to try to shrink the cancer before removing it.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColon Cancer, Rectal Cancer
CountriesUnited States
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedJun 2011
Primary CompletionJan 2013
TodayJul 2026
First PostedJun 2, 2011
Enrollment StartMay 1, 2010
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 15.1 years ago
Interventions
FOLFOX6drug
FOLFOX6
RT with concurrent chemotherapyradiation
IMRT 50.4Gy with chemotherapy
Surgeryprocedure